JOSÉ TOMÁS
RAMOS AMADOR
Catedrático de universidad
Hospital Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Carlos III (25)
2017
-
New diagnoses of human immunodeficiency virus infection in the Spanish pediatric HIV Cohort (CoRISpe) from 2004 to 2013
Medicine (United States), Vol. 96, Núm. 39
2015
-
Cardiac function in vertically HIV-infected children and adolescents in the era of highly active antiretroviral therapy
Pediatric Infectious Disease Journal, Vol. 34, Núm. 5, pp. e125-e131
2014
-
Aspectos psicosociales en una cohorte de adolescentes con infección por el virus de la inmunodeficiencia humana por transmisión vertical. NeuroCoRISpeS
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 10, pp. 631-637
-
Cardiovascular biomarkers in vertically HIV-infected children without metabolic abnormalities
Atherosclerosis, Vol. 233, Núm. 2, pp. 410-414
-
Functionally defective high-density lipoproteins are related to heightened T-cell activation in vertically HIV-infected adolescents
Journal of Acquired Immune Deficiency Syndromes, Vol. 66, Núm. 3, pp. 265-269
-
Once-daily antiretroviral therapy in a cohort of HIV-infected children and adolescents
Pediatric Infectious Disease Journal, Vol. 33, Núm. 10, pp. 1052-1054
-
Subclinical atherosclerosis and markers of immune activation in hiv-infected children and adolescents: The carovih study
Journal of Acquired Immune Deficiency Syndromes, Vol. 65, Núm. 1, pp. 42-49
2013
-
The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults
AIDS, Vol. 27, Núm. 9, pp. 1513-1516
2012
2008
-
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children
Clinical Infectious Diseases, Vol. 46, Núm. 10, pp. 1601-1608
2007
-
Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
BMC Infectious Diseases, Vol. 7
-
Prevalencia de resistencia a fármacos antirretrovirales en España
Anales de Pediatria, Vol. 67, Núm. 2, pp. 104-108
-
Slow progression of human immunodeficiency virus and hepatitis C virus disease in a cohort of coinfected children
Pediatric Infectious Disease Journal, Vol. 26, Núm. 9, pp. 846-849
2006
-
Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency [4]
Journal of Antimicrobial Chemotherapy
-
Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy
Journal of Acquired Immune Deficiency Syndromes, Vol. 43, Núm. 3, pp. 324-326
2005
-
Lopinavir/r versus nelfinavir as salvage therapy [5]
Pediatric Infectious Disease Journal
-
Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals
Pediatric Infectious Disease Journal, Vol. 24, Núm. 10, pp. 867-873
-
Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy
AIDS, Vol. 19, Núm. 18, pp. 2103-2108
2004
-
Actualización en el tratamiento antirretroviral en la infección por el virus de la inmunodeficiencia humana
Anales de Pediatria, Vol. 60, Núm. 3, pp. 254-261
-
Extensive implementation of highly active antiretroviral therapy shows great effect on survival and surrogate markers in vertically HIV-infected children
Clinical Infectious Diseases, Vol. 38, Núm. 11, pp. 1605-1612